MedTrace Logo

Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

NCT04514965 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-08-12

No results posted yet for this study

Summary

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.

Conditions

  • Primary Biliary Cirrhosis

Interventions

OTHER

Blood sampling

Blood sampling

DEVICE

Fibroscan

Measurement of liver stiffness

OTHER

Question

Question about pruritus

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Grønbæk, Prof, MD · Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04514965 on ClinicalTrials.gov